26 giug 2018 anni - FDA convened a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the new drug application for oxycodone extended-release capsules, submitted by Pain Therapeutics, with the proposed indication of the management of pain severe enough to require daily, around-the- clock, long-term opioid treatment and for which alternative treatment options are inadequate. The product is intended to have abuse-deterrent

Aggiunto al nastro di tempo:

Opioids and the FDA

ByAnastasia

13 nov 2018

0 0 333

Data: